ArticleBMJ open2025

Individualised dosimetry for holmium-166 RE in patients with unresectable hepatocellular carcinoma; a multi-centre, interventional, non-randomised, non-comparative, open label, phase II study: RHEPaiR.

Maria Qurashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.